W. Michael Gallatin, Ph.D., President
Michael Gallatin has been President and a member of the Board of Directors since he co-founded Calistoga Pharmaceuticals in March 2006. Dr. Gallatin has more than 25 years of research and development experience in oncology, immunology, and vascular biology. Dr. Gallatin was one of the founding scientists at ICOS Corporation in 1990, most recently serving as Vice President and Scientific Director of ICOS Corporation before it was acquired by Eli Lilly and Company. Prior to joining ICOS, Dr. Gallatin was a faculty member of the Fred Hutchinson Cancer Research Center in Seattle, and an affiliate faculty member of the Department of Microbiology and Immunology at the University of Washington. He has been a member of the Scientific Advisory Board of the Keystone Symposia and Caprion and currently serves in that capacity for Stromedix Corporation and the University of Texas Department of Chemistry. He is a member of the BioSeek and Seredigm Boards of Directors. Dr. Gallatin also is a Venture Partner to the Biopharma team of Frazier Healthcare Ventures.

Dr. Gallatin received his Bachelor of Science in Zoology from Truman State University and was awarded a doctorate in Immunology from the University of Alberta, Department of Immunology. He undertook his postdoctoral training at Stanford University in the laboratory of Dr. Irving Weissman.

Neill Giese, Ph.D., Chief Scientific Officer
Neill Giese has been the Chief Scientific Officer at Calistoga Pharmaceuticals since he co-founded the company in 2006. Dr. Giese has 18 years of experience in drug discovery and development in oncology, inflammation and vascular biology with a focus on mechanism-based targeted therapies for the treatment of hematologic malignancies. Prior to Calistoga, Dr. Giese was Senior Vice President of Biological Sciences and Drug Development at SGX Inc.  Prior to SGX, Dr. Giese was one of the founding scientists at COR Therapeutics, Inc. in 1989, most recently serving as Senior Director of Cancer and Cardiovascular Biology continuing in that position after it was acquired by Millennium Pharmaceuticals.

Dr. Giese received his Bachelor of Science degree in Pharmacy and Masters of Science degree in Pharmacology and Toxicology from Oregon State University and his doctorate in Pharmacology from University of Arizona.  He undertook his postdoctoral training at the National Cancer Institute, National Institutes of Health in the laboratory of Dr. Stuart Aaronson.

Roger Ulrich, Ph.D., Chief Development Officer
Roger Ulrich has been the Chief Development Officer at Calistoga Pharmaceuticals since co-founding the company in 2006. Dr. Ulrich has more than 24 years of drug discovery and development experience primarily in oncology, metabolic and infectious diseases. Prior to Calistoga, Dr, Ulrich was Senior Scientific Director with Merck Research Laboratories-Rosetta Inpharmatics where he led a team investigating molecular mechanisms and biomarkers for adverse drug reactions. Prior to Merck, Dr. Ulrich held various scientific and leadership positions including Director of Regulatory Toxicology and Safety Pharmacology with Abbott Laboratories, and as Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to that he worked at West Virginia and Michigan State Universities, and at Argonne National Laboratories. Dr. Ulrich has authored more than 115 publications and is an internationally recognized lecturer on toxicology, genomics and drug discovery. He continues to serve on various editorial boards, government and academic advisory boards and working committees.

Dr. Ulrich received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.

Daryl B. Winter, Ph.D., J.D. Chief Operating Officer
Daryl Winter joined Calistoga Pharmaceuticals in May of 2007 as its Chief Operating Officer. Dr. Winter has more than 21 years of biopharmaceutical industry experience in legal, business development and finance. From 1999 to 2007, Dr. Winter was Senior Vice President, General Counsel and corporate and board secretary for Sunesis Pharmaceuticals where, in addition to his responsibilities as General Counsel, he was responsible for intellectual property, licensing, transactions, and corporate compliance and governance. From 1989-1999, Dr. Winter worked for Genentech, Inc., where he was Senior Patent counsel and a member of the Business Development group.

Dr. Winter received his Bachelor of Science degree in Chemistry from the University of Washington, his doctorate degree in Chemistry from State University of New York, and was a NIH postdoctoral fellow in biochemistry. Dr. Winter received his law degree from Northwestern School of Law at Lewis and Clark and is a member of the Washington State and USPTO patent bars.

Albert S. Yu, M.D., Vice President, Clinical Affairs and Chief Medical Officer
Albert Yu joined Calistoga Pharmaceuticals in 2007 as its Vice President of Clinical Affairs and Chief Medical Officer. Dr. Yu has more than 15 years experience in drug development at ICOS Corporation, where from 1992 to 2007 he held various positions in clinical affairs. He was responsible for managing the clinical department as well as overseeing clinical development of multiple product candidates, including in collaboration with Eli Lilly, the development of Cialis for the treatment of erectile dysfunction.

Dr. Yu received his Bachelor of Science degree in Biology from Massachusetts Institute of Technology and his medical degree from the University of Washington. Dr. Yu is trained in internal medicine, critical care medicine and pulmonary disease.